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Intravenous bisphosphonates reduce fracture risk but
have been associated in rare cases with deteriorating
renal-function in cancer patients. The renal effects of
zoledronic acid were assessed in osteoporotic
postmenopausal women from 27 countries who received
three annual infusions of zoledronic acid or a placebo in a
randomized, double-blind trial. Serum creatinine, estimated
creatinine clearance and urinary protein were measured
before and after at least one infusion in a predefined renal
safety cohort of 5035 equally divided patients. This group
was compared to 7714 patients whose parameters were
measured annually. Significantly more transient pre- to
post-infusion increases in serum creatinine occurred in
zoledronic acid than placebo-treated patients with significant
elevations, relative to pre-infusion, only in the second year.
All 31 zoledronic acid and 8 of 10 patients on placebo
recovered their pre-infusion serum creatinine value within
12 months. No differences in mean changes in serum
creatinine, estimated creatinine clearance or adverse renal
events were found. We found that transient changes in renal
function can occur following an annual zoledronic acid
infusion but, in the long term, renal function was not
different from control patients.
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Oral bisphosphonate therapy has been shown to effec-
tively reduce fracture risk in postmenopausal women with
osteoporosis1–3 but requires frequent administration and is
associated with complex dosing instructions, variable absorp-
tion, gastrointestinal intolerance and poor compliance.4,5
Intravenous (IV) administration avoids these disadvantages
while ensuring full compliance, which may provide improved
efficacy and fracture reduction.6–9 All IV bisphosphonates are
associated with mild-to-moderate post-infusion symptoms,
occurring most commonly after the first infusion and
typically resolving within 3 days of onset. However, bisphos-
phonates are exclusively excreted via the kidneys10 and the
use of high-dose IV bisphosphonates administered over a
period of less than 15 min has been associated with deterio-
ration of renal function, primarily in the oncology setting
where other exacerbating factors, such as preexisting renal
disease and concomitant use of nephrotoxic agents, may
contribute to this impairment.11–13 Understanding the renal
impact of IV bisphosphonates in the postmenopausal
osteoporosis population thus forms an important compo-
nent in their safety evaluation.
Despite the extensive recycling of drug from plasma
to bone storage and back to plasma, bisphosphonates do
not undergo biotransformation and are mostly excreted
unchanged in urine.14 Clearance of the drug, both total and
renal, is significantly correlated with creatinine clearance.
This close correlation is most likely related to the fact that
for both bisphosphonates and creatinine, the vast majority
of renal clearance occurs via glomerular ultrafiltration.
Clinical trials have shown that, irrespective of renal
function, plasma accumulation of zoledronic acid does not
occur appreciably with sequential infusions of zoledronic
acid.13 In addition, although plasma levels of zoledronic
acid in patients with mild-to-moderate renal impairment
(estimated creatinine clearance 30–60 ml/min) are approxi-
mately 30–40% higher relative to patients with normal renal
function, this difference is small and nonsignificant; there-
fore, adjustment of zoledronic acid dosage is not necessary
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in a postmenopausal osteoporotic population. Bisphospho-
nates are not advised in patients with estimated creatinine
clearance o35 ml/min because of lack of clinical data.15
As is typically observed with all bisphosphonates, plasma
concentrations of zoledronic acid peak rapidly post-infusion
and decline in a multiphasic fashion to 1% of peak
concentrations within 24 h. This is followed by prolonged,
very low drug plasma concentrations, which represent the
recycling of drug from plasma to bone and back to plasma
by the ongoing remodeling mechanisms.14–16 Increasing the
infusion time from 5 to 15 min has been shown to lower the
peak zoledronic acid level by approximately 30% without
affecting the level of drug exposure, and results in less adverse
effects on renal function.17 Therefore, an infusion time of no
less than 15 min is strongly recommended.
This article reports the renal safety of once-yearly
zoledronic acid 5 mg given over at least 15 min in the Health
Outcomes and Reduced Incidence with Zoledronic Acid
Once Yearly–Pivotal Fracture Trial (HORIZON-PFT),8 a
randomized, double-blind, placebo-controlled study to
evaluate the efficacy and safety of zoledronic acid (5 mg) in
the treatment of osteoporosis in postmenopausal women.
RESULTS
Study population and patient disposition
The intention-to-treat, safety, and renal safety populations
comprised 7736, 7714, and 5035 patients, respectively.8 The
renal safety population included 2521 patients in the
zoledronic acid group and 2514 patients in the placebo
group. Baseline demographic and disease-related character-
istics for the safety population were similar for the two
treatment groups (Table 1). Patients in the renal safety cohort
had similar baseline characteristics to the overall population.
A total of 1219 patients (15.8%) discontinued the study. The
rates of study discontinuation (zoledronic acid, 16.2%;
placebo, 15.3%) and study discontinuation due to adverse
events (zoledronic acid, 2.1%; placebo, 1.8%) were similar in
the two treatment groups.
General safety
Zoledronic acid was generally safe and well tolerated. The
percentages of patients experiencing any adverse event
(zoledronic acid, 95.5%; placebo, 93.9%), serious adverse
events including death (zoledronic acid, 29.2%; placebo,
30.1%), and death (zoledronic acid, 3.4%; placebo, 2.9%)
were similar between treatment groups. Of 7736 randomized
patients, 22 did not receive any study medication, 7714
received the first infusion, 6926 received the second infusion
(88.3% of zoledronic-acid treated patients and 91.3% of
patients treated with placebo), and 6297 were administered
the third infusion (80.5% of zoledronic acid-treated patients
and 82.8% of patients treated with placebo).
Short-term renal safety
Measurement of serum creatinine levels 9–11 days after each
infusion showed that, overall, increases 40.5 mg/100 ml
from the pre-infusion value occurred in 0.4% (10/2338) of
placebo-treated patients and 1.3% (31/2320) of patients
treated with 5 mg of zoledronic acid (P¼ 0.001; Table 2).
Only 2/31 of the patients treated with 5 mg of zoledronic acid
had a change 40.5 mg/100 ml relative to their pre-infusion
measurement at more than one time point. The incidence of
increases by infusion with zoledronic acid 5 mg or placebo
was 0.6 vs 0.3% (P¼NS), 0.7 vs 0.1% (P¼ 0.002), and 0.5 vs
0.2% (P¼NS) after infusions 1, 2, and 3, respectively. The
percentage of patients experiencing an increase 40.5 mg/
100 ml from the pre-infusion value in the zoledronic acid
group was greatest in those with baseline estimated creatinine
clearance between 30 and 34 ml/min (10.6%) (more than
four times greater incidence than the nearest baseline
estimated creatinine clearance subgroup (35–39 ml/min)).
Increased serum creatinine levels returned to within 0.5 mg/
100 ml of the pre-infusion value in all affected patients
treated with 5 mg of zoledronic acid (n¼ 31) and in 8 of the
10 affected placebo-treated patients within 12 months. For
the 31 patients treated with 5 mg of zoledronic acid, the mean
serum creatinine levels at 9–11 days post-infusion and at
12 months post-infusion were similar after each infusion
(Figure 1).
The number of patients in whom urinary protein levels
increased from a pre-infusion level p2þ to a level 42þ
9 to 11 days post-infusion was low. Overall, this occurred in
0.58% (13/2244) of patients treated with 5 mg of zoledronic
acid compared with 0.22% (5/2262) of the placebo group
Table 1 | Patient baseline characteristics (safety population
and renal safety population)
Safety population Renal safety population
Zoledronic acid Placebo Zoledronic acid Placebo
Characteristic N=3861 N=3853 N=2521 N=2514
Race, n (%)
Caucasian 3042 (78.8) 3048 (79.1) 2105 (83.5) 2119 (84.3)
Hispanic 226 (5.9) 215 (5.6) 66 (2.6) 57 (2.3)
Othera 594 (15.4) 589 (15.3) 350 (13.9) 338 (13.4)
Age (years)
Mean (s.d.) 73 (5.3) 73 (5.4) 73 (5.4) 73 (5.4)
Range 64–89 64–89 64–89 64–89
Number of years postmenopausal, n (%)
p5 1 (o0.1) 3 (0.1) 1 (o0.1) 1 (o0.1)
45–30 2994 (77.5) 3005 (78.0) 1954 (77.5) 1940 (77.2)
430 856 (22.2) 830 (21.6) 558 (22.1) 563 (22.4)
Missing data 11 (0.3) 14 (0.4) 8 (0.3) 10 (0.4)
Creatinine clearance (ml/min)
Mean (s.d.) 63 (17.3) 64 (17.6) 64 (17.3) 64 (17.7)
Range 30.5–184.8 25.3–180.9 30.5–169.5 25.3–164.7
Urinary protein (dipstick) n (%)
o1+ 3808 (98.6) 3777 (98.1) 2481 (98.4) 2463 (98.0)
1+ 38 (1.0) 58 (1.5) 30 (1.2) 38 (1.5)
X2+b 15 (0.4) 16 (0.4) 10 (0.4) 12 (0.5)
Missing data 1 (o0.1) 1 (o0.1) 0 (0.0) 1 (0.1)
aIncludes ‘Black’, ‘Japanese’, ‘other Asian’, and ‘other’ races.
bProtocol violation.
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(P¼ 0.062). In patients treated with 5 mg of zoledronic acid,
the frequency of post-infusion urinary dipstick protein
increases to 42þ was low after all infusions with a
maximum incidence of 0.30% after infusion 2.
Long-term renal safety
No long-term differences in renal function were observed
between the patients treated with 5 mg of zoledronic acid and
those treated by placebo. Mean changes from baseline in
serum creatinine level (zoledronic acid, 0.1±0.14 mg/100 ml;
placebo, 0.1±0.15 mg/100 ml) and estimated creatinine
clearance (zoledronic acid, 8.8±9.58 ml/min; placebo,
8.7±9.62 ml/min; Figure 2) were almost identical in the
two treatment groups over the 3 years of the study. Moreover,
at month 36, 3.2% of patients in both groups had estimated
creatinine clearance o30 ml/min.
Overall, at any time during the study, the incidence of
renal abnormalities was similar between treatment groups
(Table 3). These included reported renal adverse events
(zoledronic acid, 4.9%; placebo, 4.4%), estimated creatinine
Table 2 | Short-term renal safety: pre- to post-infusion changes in serum creatinine level and in urinary protein level
(renal safety population)
Zoledronic acid Placebo
Timing of visit N n (%) N n (%) P-value
9–11 days after 1st infusion
Increase in serum creatinine 40.5 mg/100 ml 2114 13 (0.61) 2130 6 (0.28) 0.113
Urinary protein level 42+a 2086 6 (0.29) 2101 3 (0.14) 0.342
9–11 days after 2nd infusion
Increase in serum creatinine 40.5 mg/100 ml 1663 12 (0.72) 1721 1 (0.06) 0.002
Urinary protein level 42+a 1645 5 (0.30) 1706 2 (0.12) 0.280
9–11 days after 3rd infusion
Increase in serum creatinine 40.5 mg/100 ml 1560 8 (0.51) 1600 3 (0.19) 0.141
Urinary protein level 42+a 1468 3 (0.20) 1515 1 (0.07) 0.367
Overall (that is, any 9–11 day post-infusion visit)
Increase in serum creatinine 40.5 mg/100 ml 2320 31 (1.34) 2338 10 (0.43) 0.001
Urinary protein level 42+a 2244 13 (0.58) 2263 5 (0.22) 0.062
aEvaluation restricted to patients with pre-infusion reading p2+; evaluated using dipstick.
N: number of patients with evaluable data.
n: number of patients affected.
Serum creatinine levels (mean [s.d.], max) 9–11 days post-infusion.
Zoledronic acid 1st infusion: 0.774 [0.210] mg/100 ml, 4.005 mg/100 ml; 2nd infusion: 0.805 [0.199] mg/100 ml, 2.195 mg/100 ml; 3rd infusion: 0.828 [0.203] mg/100 ml,
2.500 mg/100 ml.
Placebo 1st infusion: 0.803 [0.193] mg/100 ml, 3.495 mg/100 ml; 2nd infusion: 0.812 [0.181] mg/100 ml, 1.900 mg/100 ml; 3rd infusion: 0.836 [0.188] mg/100 ml,
2.104 mg/100 ml.
3.5
3
2.5
1.5
0.5
2
1
0
M
ea
n 
se
ru
m
 c
re
a
tin
in
e 
(m
g/1
00
 m
l)
Baseline 9–11 days
after first
infusion
9–11 days
after second
infusion
9–11 days
after third
infusion
2nd
infusion
(month 12)
3rd
infusion
(month 24)
Month 36
Zoledronic acid
n=
Placebo
n=
31
10 88 8 87 7
2929 21 26 19 24
Placebo
Zoledronic acid 5 mg
Figure 1 | Mean serum creatinine levels from baseline to 36 months in patients with pre- to post-infusion change of
40.5 mg/100 ml. For each infusion, the patients treated with 5 mg of zoledronic acid showed similar mean serum creatinine levels at
9–11 days post-infusion and also at 12 months post-infusion.
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clearanceo30 ml/min (zoledronic acid, 4.4%; placebo, 4.2%;
P¼NS), estimated creatinine clearance decreases X30% in
patients with baseline value p60 ml/min (zoledronic acid,
5.0%; placebo, 4.8%; P¼NS), and increased proteinuria
(zoledronic acid, 0.5%; placebo, 0.5%; P¼NS) (42þ in
patients with baseline level p2þ ; zoledronic acid, 0.5%;
placebo, 0.5%; P¼NS). Increases from baseline in serum
creatinine level 40.5 mg/100 ml were 2.8% with zoledronic
acid and 2.0% with placebo (P¼NS).
Renal safety in patients with mild-to-moderate renal
impairment
Renal safety in patients with mild-to-moderate renal
impairment was evaluated in patients with baseline estimated
creatinine clearance between 30 and 60 ml/min. Overall, for
zoledronic acid-treated patients, the incidence of an increase
in serum creatinine 40.5 mg/100 ml relative to baseline was
similar in patients whose baseline estimated creatinine
clearance was o60 ml/min compared with those whose
baseline estimated creatinine clearance was X60 ml/min
(21 (1.99%) of 1053 patients vs 21 (1.66%) of 1267 patients,
respectively; Table 4).
Moreover, in the short term, no differences were
observed in the incidence of an increase in serum creatinine
40.5 mg/100 ml in patients with an estimated creatinine
clearance of 35 to p60 ml/min and 460 ml/min adminis-
tered 5 mg of zoledronic acid compared with placebo.
In patients with an estimated creatinine clearance between
30 and 35 ml/min, five patients in the group treated with
5 mg of zoledronic acid had an increase in serum creatinine
40.5 mg/100 ml compared with one patient in the placebo
group.
The incidence of patients developing treatment-emergent
estimated creatinine clearance o30 ml/min was greater for
patients with a baseline calculated estimated creatinine
clearance o40 ml/min in both treatment groups and is
consistent with the average decline in renal function of the
overall population—approximately 8 ml/min over 3 years.
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Figure 2 | Long-term renal safety: mean change in
estimated creatinine clearance from baseline to 36 months
(safety population). At month 36, the mean (±s.e.m.) decrease
from baseline in estimated creatinine clearance was similar
in the patients treated with 5 mg of zoledronic acid
(8.75±0.175 ml/min) and in the placebo group
(8.67±0.175 ml/min).
Table 3 | Long-term renal safety: changes from baseline in estimated creatinine clearance, serum creatinine, and urinary
protein levels (safety population)
Endpoint
Zoledronic acid Placebo
Timing of data collection N n (%) N n (%) P-value
Increase in serum creatinine 40.5 mg/100 ml
Before 2nd infusion (month 12) 3595 19 (0.53) 3624 9 (0.25) 0.060
Before 3rd infusion (month 24) 3289 16 (0.49) 3345 20 (0.60) 0.617
Month 36 3022 36 (1.19) 3066 38 (1.24) 0.907
Overall (that is, at any time during the study) 3752 104 (2.77) 3767 77 (2.04) 0.042
Urinary protein level 42+a
Before 2nd infusion (month 12) 3581 1 (0.03) 3606 3 (0.08) 0.625
Before 3rd infusion (month 24) 3277 3 (0.09) 3323 5 (0.15) 0.482
Month 36 2980 2 (0.07) 3021 5 (0.17) 0.453
Overall (that is, at any time during the study) 3749 19 (0.51) 3758 19 (0.51) 1.000
Estimated creatinine clearance o30 ml/min
Before 2nd infusion (month 12) 3574 49 (1.37) 3615 44 (1.22) 0.602
Before 3rd infusion (month 24) 3284 57 (1.74) 3337 63 (1.89) 0.647
Month 36 2994 97 (3.24) 3035 96 (3.16) 0.884
Overall (that is, at any time during the study) 3621 160 (4.42) 3658 152 (4.16) 0.603
Estimated creatinine clearance decreased by X30%b
Before 2nd infusion (month 12) 3574 40 (1.12) 3615 35 (0.97) 0.563
Before 3rd infusion (month 24) 3284 63 (1.92) 3338 69 (2.07) 0.725
Month 36 2994 110 (3.67) 3035 98 (3.23) 0.359
Overall (that is, at any time during the study) 3621 182 (5.03) 3658 177 (4.84) 0.745
aEvaluation restricted to patients with baseline reading p2+; evaluated using dipstick.
bEvaluation restricted to patients with baseline value p60 ml/min.
N: number of patients with evaluable data.
n: number of patients affected.
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There was no relationship between the percentage change
in creatinine clearance and baseline creatinine clearance
(Table 4).
Renal failure
Acute renal failure (that is, serious adverse event requiring
hospitalization) was reported in four patients treated with
5 mg zoledronic acid (0.10%) and in three placebo-treated
patients (0.08%), based on an investigator’s judgement of
whether changes in creatinine clearance constituted an
adverse event. That is, the determination of acute renal
failure was subjective and was not based on any prespecified
criteria, as evidenced by the fact that two of the four
zoledronic acid-treated patients considered to have developed
renal failure had baseline creatinine clearances of 31 ml/min
and had only small changes below 30 ml/min. The overall
incidence of reported renal failure was also similar between
groups (zoledronic acid, 0.10%; placebo, 0.18%).
DISCUSSION
The Health Outcomes and Reduced Incidence with Zole-
dronic Acid Once Yearly–Pivotal Fracture Trial was a large,
randomized, double-blind, placebo-controlled trial that
monitored short-term renal function in more than 5000
patients, and long-term renal function in the entire safety
population of 7714 patients.8 The results showed no
association between annual infusions of 5 mg of zoledronic
acid and long-term deterioration of renal function in
osteoporotic postmenopausal women with estimated creati-
nine clearanceX30 ml/min at baseline: long-term changes in
renal function, renal adverse events and renal impairment
occurred with similar frequency in the zoledronic acid- and
placebo-treated groups. Gradual deterioration of renal
function with time was observed in both the active treatment
and placebo groups in the HORIZON-PFT study (Figure 2),8
consistent with age-related effects on renal function.
This study demonstrated that annual infusions of 5 mg of
zoledronic acid may be associated with transient, short-term
increases in serum creatinine only, as demonstrated by the
similar long-term changes in calculated creatinine clearance
observed in both treatment groups. Follow-up of the
31 patients treated with 5 mg of zoledronic acid who
experienced short-term significant increases in serum creati-
nine showed that the increased serum creatinine levels had
returned to within 0.5 mg/100 ml of the pre-infusion values
within 12 months, demonstrating no cumulative effect on
renal function in this population when multiple annual
infusion doses of 5 mg of zoledronic acid are administered
over a period no shorter than 15 min. Further corroborating
this notion are the results obtained in the analyses of patients
with mild-to-moderate renal impairment (estimated creati-
nine clearance between 30 and 60 ml/min). The proportion
of patients whose estimated creatinine clearance decreased to
o30 ml/min or decreased 430% from baseline during the
study was similar between treatment groups for all categories
of baseline creatinine clearance.
The change in renal function was determined by changes
in serum creatinine values 40.5 mg/100 ml higher than the
value at pre-infusion or at baseline. These changes, rather
than changes in creatinine clearance, were used because they
require practical and less expensive methods of measurement
for the non-nephrology clinical setting used in the study.18
Treatment of postmenopausal osteoporosis is only one of
the several indications for bisphosphonates and for zole-
dronic acid in particular. For example, zoledronic acid is
approved for the treatment of Paget’s disease of bone,19
hypercalcemia of malignancy, multiple myeloma, and bone
metastases of solid tumors.20
Several case reports have shown changes in renal function
in association with zoledronic acid infusion in oncology
patients, particularly with more rapid infusions (of 5 min
duration), although the specific role of zoledronic acid
treatment is difficult to determine in the presence of various
risk factors in these patients.21–23 Most oncology regimens20
are considerably more intensive than the single, annual
administration of 5 mg of zoledronic acid used in this trial,8
and in addition, dehydration, renal dysfunction, and the use
of nephrotoxic drugs are common in cancer patients.12,24,25
Table 4 | Patients developing increases in serum creatinine 40.5 mg/100 ml relative to baseline 9–11 days post-infusion, and
those developing treatment-emergent estimated creatinine clearance o30 ml/min or a decrease in estimated creatinine
clearance 430% during the trial
Zoledronic acid Placebo
Serum creatinine increase
40.5 mg/100 ml
Estimated CrCl
o30 ml/min
Estimated CrCl
decrease 430%
Serum creatinine increase
40.5 mg/100 ml
Estimated CrCl
o30 ml/min
Estimated CrCl
decrease 430%
Baseline CrCl N n (%) N n (%) N n (%) N n (%) N n (%) N n (%)
o30 ml/min 0 0 0 0 0 0 3 0 (0.00) 3 3 (100.00) 3 1 (33.33)
30–35 ml/min 47 5 (10.64) 68 38 (55.66) 68 6 (8.82) 65 1 (1.54) 84 53 (63.10) 84 9 (10.71)
35–40 ml/min 84 2 (2.38) 146 52 (35.62) 146 23 (15.75) 95 3 (3.16) 133 42 (31.58) 133 18 (13.53)
40–50 ml/min 372 7 (1.88) 573 49 (8.55) 573 70 (12.22) 358 4 (1.12) 589 42 (7.13) 589 64 (10.87)
50–60 ml/min 550 7 (1.27) 861 16 (1.86) 891 83 (9.32) 513 2 (0.39) 803 8 (1.00) 834 85 (10.19)
460 ml/min 1267 21 (1.66) 1973 5 (0.25) 1678 182 (10.85) 1304 9 (0.69) 2064 4 (0.20) 1634 177 (10.77)
All patients 2320 42 (1.81) 3621 160 (4.42) 2338 19 (0.81) 3658 152 (4.16)
CrCl: creatinine clearance.
N: number of patients with evaluable data.
n: number of patients affected.
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Data from short- and long-term studies have shown that the
renal safety profile of high-dose zoledronic acid is similar to
IV pamidronate in breast cancer and multiple myeloma, and
to placebo in prostate cancer, lung cancer, and other solid
tumors.26 Interpretation of the results from this study in the
context of existing published safety data should recognize the
inherent differences in baseline characteristics between cancer
and osteoporosis patients and take into account the different
zoledronic acid dosing regimens used in these two patient
populations.
Both equations for estimating glomerular filtration rate,
that is, Cockcroft–Gault and modification of diet in renal
disease, are useful in clinical practice to estimate renal
function.27 When compared to one of the ‘gold standards’ for
measuring glomerular filtration rate (51Cr-EDTA), both
estimated equations show very limited biases and fit closely
on a line of unity in a linear manner to true glomerular
filtration rate measurements in large population studies.
Both formulae may have limited precision in subgroups,
particularly in younger subjects (o65 years of age), or very
thin subjects for modification of diet in renal disease
(o18 kg/m2), and obese individuals for Cockcroft–Gault
(BMI 430 kg/m2). As the cohort of the zoledronic acid
patients in the HORIZON-PFT study were mainly aged above
65 years and not obese, the Cockcroft–Gault formula
provided a valid estimation for glomerular filtration rate in
this study population.
The results of this study show that the transient short-
term changes that may occur with annual infusions of 5 mg
of zoledronic acid over 15 min are not associated with long-
term detrimental effects in postmenopausal osteoporotic
patients who have normal renal function or mild-to-
moderate renal dysfunction at baseline. This is important
from a clinical standpoint, as it confirms that modifying the
present treatment regimen (5 mg of zoledronic acid annually,
infused over a minimum period of 15 min) is not necessary
in patients with a baseline estimated creatinine clearance
X30 ml/min and removes the need to place further
restrictions on the osteoporotic population that can benefit
from this treatment.
As annual administration of zoledronic acid for 3 years
has been shown to reduce the risk of new vertebral and hip
fractures by 70 and 41%, respectively,8 the benefits of
treatment are substantial. However, for patients with
increased risk for adverse events, that is, those with reduced
renal function (estimated creatinine clearance between 30
and 35 ml/min), and for those at increased risk of renal
adverse events (for example, elderly patients and those with
hypertension or diabetes mellitus), sound clinical manage-
ment is advised. In particular, this should involve ensuring
that the patient is well hydrated before and after infusion
of zoledronic acid and that the infusion time is not less
than 15 min.
In conclusion, we have shown that multiple annual
infusions of 5 mg of zoledronic acid, when infused over a
minimum period of 15 min, are safe and generally well
tolerated in women with postmenopausal osteoporosis.
Although zoledronic acid administration may be associated
with short-term effects on renal function, especially in
patients with estimated creatinine clearance between 30
and 35 ml/min, these changes are very uncommon, mild,
and transient and are not associated with any long-term
detrimental effect. As the gradual reductions in renal
function that occurred in the zoledronic acid and placebo
treatment groups in this study were of identical magnitude,
we can conclude that three annual zoledronic acid infusions
have no long-term detrimental effect on renal function in
patients with postmenopausal osteoporosis with baseline
estimated creatinine clearance 430 ml/min.
MATERIALS AND METHODS
Study design and subjects
The Health Outcomes and Reduced Incidence with Zoledronic Acid
Once Yearly–Pivotal Fracture Trial was an international, multicenter,
randomized, double-blind, placebo-controlled trial carried out
in 239 centers in 27 countries.8 The study population comprised
7736 postmenopausal women aged 65–89 years with osteoporosis
documented by either: (i) femoral neck bone mineral density
T-score p2.5 with or without evidence of vertebral fracture; or
(ii) a bone mineral density T-score of p1.5 with radiologic
evidence of at least two mild or one moderate existing (prevalent)
vertebral fracture(s). Exclusion criteria included use of IV bisphos-
phonates in the 2 years before randomization, use of oral
bisphosphonates not in accordance with the washout schedule,
previous use of strontium, hypercalcemia, hypocalcemia, and renal
disease (estimated creatinine clearance o30.0 ml/min, urinary
protein X2þ (dipstick reading), or increase of 40.5 mg/100 ml
in serum creatinine between the two screening visits). Creatinine
clearance was estimated using the Cockcroft–Gault equation:
CCrðml=minÞ ¼ ð140  age½yearsÞbody weight ðkgÞ0:85
72SCrðmg=100mlÞ
After a screening period of up to 2 months, patients were
randomized to receive placebo or 5 mg of zoledronic acid as a
15 min IV infusion on day 0, and approximately 12 and 24 months
later, a total of three annual treatments (Figure 3). Serum creatinine
and estimated creatinine clearance were determined in all patients
within 3 weeks before any dose of study medication. No patient
was dosed if their estimated creatinine clearance decreased to
o30 ml/min. All participants were instructed to take 1000–1500 mg
of elemental calcium and 400–1200 IU of vitamin D daily. Patients
were placed into one of two strata on the basis of whether they were
taking any osteoporosis medications at baseline. Patients in stratum
one were not taking any osteoporosis medications at the time of
Day 0
first
infusion MV MV
Month 12
second
infusion
Month 36
safety
evaluationMV
Month 24
third
infusion
9–11 days9–11 days9–11 days
Screening period
(≤ 2 months)
MV, monitoring visit
included pre-treatment assessment of renal function
Figure 3 | Renal safety monitoring schedule during the
HORIZON-PFT study.
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randomization, whereas patients in stratum two were permitted
to receive concomitant osteoporosis medication, which included
hormone replacement therapy, raloxifene, calcitonin, tibolone,
tamoxifen, ipriflavone, dehydroepiandrosterone(s), and medroxy-
progesterone.
Safety monitoring
General safety was assessed by routine monitoring of adverse events,
clinical laboratory evaluations, measurement of vital signs, and
physical examination. Patients who discontinued from study drug
were encouraged to remain in the study for follow-up efficacy and
safety evaluations. Specific monitoring of renal function was also
carried out. Short-term renal effects were evaluated by measuring
serum creatinine and urinary dipstick protein levels 9–11 days after
each infusion in a subset of patients designated as the ‘renal safety
cohort’. A patient was included in this cohort if they had at least one
baseline and at least one post-randomization measurement of serum
creatinine or a urine dipstick (zoledronic acid, n¼ 2521; placebo,
n¼ 2514). Post-infusion serum creatinine values were compared
with values obtained at baseline and with the pre-infusion value.
Baseline values of serum creatinine and estimated creatinine
clearance were defined as the average of the last two measurements
taken before randomization. For all other parameters, the baseline
value was the last measurement obtained before administration of
the first dose of study medication. On subsequent visits, if more
than one pre-infusion serum creatinine measurement was taken, the
most recent was used. All post-infusion urinary dipstick protein
values were compared with data obtained at baseline and the pre-
infusion value. Long-term renal effects were evaluated in all patients
by determining estimated creatinine clearance, serum creatinine,
and urinary protein levels before treatment administration of
infusion 2 (month 12) and infusion 3 (month 24), and at the final
visit (month 36 or early termination). These values were compared
with those obtained at baseline.
All potential renal events were assessed by a three-member
panel of renal experts who were independent of the clinical trial
team. The panel predefined search terms on the basis of codes from
the Medical Dictionary for Regulatory Activity-preferred terms.
Investigators at each clinical center collected medical documentation
for the cases. The documentation was forwarded to the expert panel
for blinded event adjudication to determine if they met the criteria
of a clinically relevant change in renal function. Adjudication of
individual events was triggered by the following: (i) serum
creatinine value 40.5 mg/100 ml higher than the value obtained
pre-infusion or at baseline; (ii) estimated creatinine clearance
o30 ml/min; (iii) X30% decrease in estimated creatinine clearance
when baseline value wasp60 ml/min; and (iv) any reported adverse
event associated with a change in renal function.
Statistical analysis
The analyses of renal safety involved two populations: the safety
population (all subjects in the intention-to-treat population who
received at least one infusion of study drug), and the renal safety
population (a subset of the safety population that included all
patients with a baseline serum creatinine measurement and at
least one post-treatment measurement of serum creatinine or
urinary protein 9–11 days after treatment). All safety analyses were
performed using observed data, and there was no imputation
of missing data. Descriptive statistics were used to describe patient
characteristics at baseline (intention-to-treat and renal safety popu-
lation) and renal safety data (short-term, renal safety population;
long-term, safety population). P values were calculated using the
Fisher’s exact test, as appropriate.
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